- Synaptogenix, an emerging biopharmaceutical company working on treatments for brain-related disorders, recently shared findings from their Phase 2 trial on a drug called Bryostatin-1 for Alzheimer’s disease.
- The results of a recent phase 2 clinical trial indicate that Bryostatin-1 may halt cognitive decline in patients with severe Alzheimer’s, in contrast to placebo recipients who demonstrated a drop in cognitive function.
- This novel drug has previously shown potential in lab settings, bolstering brain connections and offering protection against Alzheimer’s-related proteins.
A new study published in the Journal of Alzheimer’s Disease — covering a phase 2 clinical trial spearheaded by scientists affiliated with the biopharmaceutical company Synaptogenix — looked at how Alzheimer’s patients responded to a a new experimental drug, Bryostatin-1 over 6 months.
For those with severe Alzheimer’s, the drug seemed to prevent further cognitive decline when compared to those on a placebo, who showed a drop in their cognitive scores.
In recent laboratory studies, a compound known as Bryostatin has shown promise in supporting brain connections and combating signs of Alzheimer’s disease.
With a molecular weight of 904, the experimental drug appeared to enhance neural connections, protect brain cells from premature death, and counteract harmful proteins linked to Alzheimer’s.
The primary aim of the recent trial was to determine if Alzheimer’s patients could benefit cognitively from regular doses of Bryostatin compared to a placebo.
Researchers observed 122 Alzheimer’s patients over 6 months. These participants were divided into two main groups based on the severity of their cognitive impairment, as measured by the Mini-Mental Status Exam (MMSE).
One group had moderate cognitive impairment, scoring between MMSE 15-18, and the other had more severe impairment, scoring between MMSE 10-14.
To ensure a fair comparison, patients were grouped according to their initial…
Read the full article here